Inada T, Kawakubo H, Ichikawa A, Ogata Y
Dept. of Surgery, Tochigi Cancer Center.
Gan To Kagaku Ryoho. 1999 Feb;26(3):315-20.
The prognostic influence of post-operative adjuvant chemotherapy on stage I b or II gastric cancer was studied retrospectively. The immunohistochemical expressions of p53 protein and thymidine phosphorylase (TP) were also examined; the relations between these protein expressions and clinicopathological features along with the effect of adjuvant chemotherapy were also investigated. The 5-year survival rate of the patients who received adjuvant chemotherapy was 95.5%, which was better than that (89.8%) of those who did not, although the difference did not reach significance (p = 0.09). The venous invasion of tumor was slight frequently observed in p53 or TP positive cases than negative cases, respectively (p < 0.1), but no significant associations were found between the t-, n- or ly-factor, and p53 or TP expression. Moreover p53 and TP expression had no significant influence on post-operative survival. But, among the patients with p53- or TP-positive tumor, adjuvant chemotherapy conferred survival benefits, although the difference did not reach significance. The 5-year survival rate was 100% with adjuvant chemotherapy, 84.3% without chemotherapy in p53-positive patients (p = 0.137), 97.0% with adjuvant chemotherapy, and 90.8% without chemotherapy in TP-positive tumors (p = 0.326).
我们对术后辅助化疗对Ⅰb期或Ⅱ期胃癌的预后影响进行了回顾性研究。同时检测了p53蛋白和胸苷磷酸化酶(TP)的免疫组化表达情况;研究了这些蛋白表达与临床病理特征之间的关系以及辅助化疗的效果。接受辅助化疗患者的5年生存率为95.5%,虽优于未接受辅助化疗患者的5年生存率(89.8%),但差异无统计学意义(p = 0.09)。p53或TP阳性病例中肿瘤的静脉侵犯分别比阴性病例更常表现为轻微(p < 0.1),但在t、n或ly因子与p53或TP表达之间未发现显著相关性。此外,p53和TP表达对术后生存无显著影响。但是,在p53或TP阳性肿瘤患者中,辅助化疗可带来生存获益,尽管差异无统计学意义。p53阳性患者接受辅助化疗的5年生存率为100%,未接受化疗的为84.3%(p = 0.137);TP阳性肿瘤患者接受辅助化疗的5年生存率为97.0%,未接受化疗的为90.8%(p = 0.326)。